These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16445950)

  • 1. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.
    Reale M; Iarlori C; Gambi F; Feliciani C; Isabella L; Gambi D
    Neuropharmacology; 2006 Apr; 50(5):606-13. PubMed ID: 16445950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease.
    Iarlori C; Gambi D; Gambi F; Lucci I; Feliciani C; Salvatore M; Reale M
    Exp Gerontol; 2005 Jul; 40(7):605-11. PubMed ID: 15935590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients.
    Reale M; Iarlori C; Gambi F; Lucci I; Salvatore M; Gambi D
    Exp Gerontol; 2005 Mar; 40(3):165-71. PubMed ID: 15763393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines.
    Reale M; Iarlori C; Gambi F; Feliciani C; Salone A; Toma L; DeLuca G; Salvatore M; Conti P; Gambi D
    J Neuroimmunol; 2004 Mar; 148(1-2):162-71. PubMed ID: 14975597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease.
    Cancelli I; Cadore IP; Merlino G; Valentinis L; Moratti U; Bergonzi P; Gigli GL; Valente M
    J Clin Neurophysiol; 2006 Oct; 23(5):421-5. PubMed ID: 17016152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors.
    Lugaresi A; Di Iorio A; Iarlori C; Reale M; De Luca G; Sparvieri E; Michetti A; Conti P; Gambi D; Abate G; Paganelli R
    Exp Gerontol; 2004 Apr; 39(4):653-7. PubMed ID: 15050302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cutaneous vascular response in AD subjects under donepezil therapy.
    Maltz JS; Eberling JL; Jagust WJ; Budinger TF
    Neurobiol Aging; 2004 Apr; 25(4):475-81. PubMed ID: 15013568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.
    Richardson C; Gard PR; Klugman A; Isaac M; Tabet N
    Int J Geriatr Psychiatry; 2013 Dec; 28(12):1312-7. PubMed ID: 23585364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
    Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
    Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
    Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production.
    Pellicanò M; Bulati M; Buffa S; Barbagallo M; Di Prima A; Misiano G; Picone P; Di Carlo M; Nuzzo D; Candore G; Vasto S; Lio D; Caruso C; Colonna-Romano G
    J Alzheimers Dis; 2010; 21(1):181-92. PubMed ID: 20413861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system.
    Zivin M; Pregelj P
    Psychiatr Danub; 2008 Jun; 20(2):168-73. PubMed ID: 18587286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of donepezil on innate antiviral immunity of human leukocytes.
    Sochocka M; Zaczyńska E; Leszek J; Siemieniec I; Błach-Olszewska Z
    J Neurol Sci; 2008 Oct; 273(1-2):75-80. PubMed ID: 18662817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells.
    Gambi F; Reale M; Iarlori C; Salone A; Toma L; Paladini C; De Luca G; Feliciani C; Salvatore M; Salerno RM; Theoharides TC; Conti P; Exton M; Gambi D
    J Clin Psychopharmacol; 2004 Jun; 24(3):314-21. PubMed ID: 15118486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl Cholinesterase Inhibitors and Cell-Derived Peripheral Inflammatory Cytokines in Early Stages of Alzheimer's Disease.
    Kokras N; Stamouli E; Sotiropoulos I; Katirtzoglou EA; Siarkos KT; Dalagiorgou G; Alexandraki KI; Coulocheri S; Piperi C; Politis AM
    J Clin Psychopharmacol; 2018 Apr; 38(2):138-143. PubMed ID: 29420357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
    Bartha R; Smith M; Rupsingh R; Rylett J; Wells JL; Borrie MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):786-93. PubMed ID: 18252268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
    Galimberti D; Fenoglio C; Lovati C; Venturelli E; Guidi I; Corrà B; Scalabrini D; Clerici F; Mariani C; Bresolin N; Scarpini E
    Neurobiol Aging; 2006 Dec; 27(12):1763-8. PubMed ID: 16307829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of donepezil on EEG spectral analysis in Alzheimer's disease.
    Balkan S; Yaraş N; Mihçi E; Dora B; Ağar A; Yargiçoğlu P
    Acta Neurol Belg; 2003 Sep; 103(3):164-9. PubMed ID: 14626697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.